| Document |
Document Title |
|
WO/2023/212443A1 |
The present disclosure includes methods of treating a disease or condition that produces skin inflammation and/or itch. More specifically the present disclosure relates to treating skin inflammation and itch caused by diseases or disorde...
|
|
WO/2023/208028A1 |
Provided is a method for treating psoriasis or Alzheimer's disease in a subject, comprising administering to the subject a therapeutically effective amount of circular RNA with a 16 bp-26 bp double-stranded stem-loop structure.
|
|
WO/2023/210059A1 |
Provided is a new means for delivering a useful component into the skin. This dermatological topical agent composition is characterized by containing a fine acicular crystals of taurine including a useful component in the crystals. Acc...
|
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
|
WO/2023/212365A1 |
This disclosure relates to topical formulations (including scalp essences, scalp cleansers, and scalp masks) for balancing the scalp microbiome and uses thereof to improve hair health or scalp health or treat or prevent hair loss.
|
|
WO/2023/210740A1 |
The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
|
|
WO/2023/209568A1 |
Described herein are multispecific antibodies targeting IL-13 and IL-18. The multispecific antibodies can be antagonistic and/or therapeutic antibodies targeting IL-13 and IL-18. Also described herein are methods of making said multispec...
|
|
WO/2023/210402A1 |
The present invention provides a method for evaluating the hair regeneration ability of dermal sheath cup (DSC) cells using a mitochondrial respiration level as an indicator. The present invention also provides a composition for hair reg...
|
|
WO/2023/186174A9 |
Provided herein is a gel composition for topical use, which comprises an IL-17 A binding molecule and suitable excipients.
|
|
WO/2023/210410A1 |
In order to provide a novel wound healing agent having a high wound healing effect, the present invention uses a wound healing agent containing, as an active ingredient, Tsukushi protein, a partial peptide of the Tsukushi protein, or an ...
|
|
WO/2023/209036A1 |
Provided herein are methods of treating bullous pemphigoid using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of bullous pemphigoid and for use in the manufacture of a m...
|
|
WO/2023/211728A1 |
Methods of promoting healing of a wound in a dermal location of a subject are provided. Aspects of the methods may include administering an effective amount of a Piezo inhibitor composition to the wound to promote healing of the wound, e...
|
|
WO/2023/210401A1 |
The purpose of the present invention is to elucidate the relationship between lymph vessels in the skin and lymphedema as well as the relationship between lymph vessels in the skin and the skin, and to provide thereby a method for evalua...
|
|
WO/2023/209655A1 |
The present invention relates to a cosmetic use of a composition for boosting skin cell energy metabolism in an individual, wherein the composition comprises a compound of formula I, wherein the carbon-carbon bond noted Formula II is a d...
|
|
WO/2023/201858A1 |
The present invention relates to the technical field of hair growth. Disclosed is a medication for treating androgenetic alopecia. The effective components of the medication are epristeride, or epristeride and finasteride, or epristeride...
|
|
WO/2023/202580A1 |
Disclosed are a composition of a microemulsion foam for treating alopecia areata, atopic dermatitis and vitiligo, and a preparation method therefor. The active ingredients are a JAK inhibitor and a pharmaceutically acceptable salt thereo...
|
|
WO/2023/201859A1 |
The present invention relates to the technical field of hair growth. Disclosed is an epristeride external preparation for preventing and treating androgenetic alopecia. According to the epristeride external preparation, the pharmaceutica...
|
|
WO/2023/202102A1 |
The present invention relates to the technical field of biomedicine, it has been found in the present invention that a compound shown in formula I, or an optical isomer or racemate thereof, or a solvate thereof, or a pharmaceutically acc...
|
|
WO/2023/204608A1 |
The present invention relates to a cosmetic composition and food composition for improving skin, comprising potato-derived exosomes.
|
|
WO/2023/204754A1 |
A method of treating an autoimmune skin disease in a patient comprising administering a therapeutically effective amount of a DHODH inhibitor or a pharmaceutically acceptable salt thereof. Also provided are formulations or compositions s...
|
|
WO/2023/204363A1 |
The present invention relates to a composition for preventing, ameliorating, or treating atopic dermatitis comprising an extract of Alpinia officinarum Hance as an active ingredient. Specifically, as an extract of Alpinia officinarum Han...
|
|
WO/2023/203022A1 |
Provided is a PDE4 inhibitor, in particular orismilast or a pharmaceutically acceptable salt, solvate or hydrate thereof, for use in the treatment of neutrophilic dermatoses in a subject. In particular, the invention provides orismilast ...
|
|
WO/2023/202989A1 |
The present invention relates to the treatment of frontal fibrosing alopecia. The problem to be solved by the invention is to provide a new pharmaceutical use of 3- [(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-di
azaspiro[3....
|
|
WO/2023/202642A1 |
The present invention relates to a Rho-associated protein kinase inhibitor and preparation and use thereof. Specifically, the compound of the present invention has a structure represented by formula I, wherein the definitions of each gro...
|
|
WO/2023/205251A1 |
Disclosed are compounds of formula (I) which modulate bromodomains, pharmaceutical compositions containing said compounds and use of said compounds in therapy.
|
|
WO/2023/201998A1 |
The present invention relates to a skin medication technology, and in particular to an application of a hydroxybetulinic acid compound in treatment of skin diseases, especially eczema, inflammatory skin diseases, and allergic shock. Acco...
|
|
WO/2023/202439A1 |
The present application provides use of a diterpene compound derivative or a salt thereof in the preparation of a medicine for preventing and treating atopic dermatitis. The micromolecular diterpene compound derivative or the salt thereo...
|
|
WO/2023/201397A1 |
Disclosed herein is a bioactive polymer for forming a tissue scaffold, the polymer comprising a first monomer for binding water, a second monomer for imparting mechanical properties to the scaffold; optionally, a third monomer for bindin...
|
|
WO/2023/205386A1 |
An anti-inflammatory and inflammation pro-resolving composition comprising an Anetholea anisita extract for improving hair and scalp condition is provided.
|
|
WO/2023/203008A1 |
A composition comprising nicotinamide and low-molecular-weight HPMC and/or HPC, characterized in that the composition is formulated for oral administration with at least partially extended and/or sustained and/or controlled release of ni...
|
|
WO/2023/203549A1 |
Disclosed herein are methods of treating psoriasis and other IL-17-dependent conditions with an anti-interleukin 17A/F nanobody for approximately 24 weeks, followed by withdrawal of treatment in responding patients with the anti-interleu...
|
|
WO/2023/167894A9 |
Composition comprising an active agent selected among sclareol, sclareol-like, sclareolide or sclareolide-like for use in preventing or treating inflammatory skin conditions including atopic dermatitis and seborrheic dermatitis by applic...
|
|
WO/2023/197914A1 |
Provided is novel use of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof in preventing or treating hypersensitivity or an autoimmune inflammation-related disorder.
|
|
WO/2023/199196A1 |
The present technology provides the crystalline phosphate, malonate, and malate salts of 3- (2-amino-1,3-benzoxazol-5-yl)-1-(1,3-dimethylbutyl)pyrazolo[
3,4-d]pyrimidine-4,6-diamine. The present technology further provides methods for pr...
|
|
WO/2023/198800A1 |
The present invention relates to new compositions combining at least one inorganic solar filter and to the use thereof in cosmetics, and to the pharmaceutical use thereof, in particular in dermatology, in particular as solar protection f...
|
|
WO/2023/199024A1 |
The invention relates to methods for promoting and maintaining cell differentiation and gene expression in a subject, and ensuring that longer genes are able to function, the method comprising administering citrate to a subject. The inve...
|
|
WO/2023/198873A1 |
The application relates to isoxazolyl-pyrazole derivatives of the general formula (I) for the treatment of diseases and conditions such as psoriasis, autoimmune thyroiditis, inflammatory bowel disease and cancer in which inverse agonism ...
|
|
WO/2023/198876A1 |
The present invention relates to a topical formulation comprising at least one anticholinergic compound for use in treating patients suffering from severe hyperhidrosis, wherein administration of the formulation to the patient comprises:...
|
|
WO/2023/200786A1 |
Diarylalkane compounds for use in anti-aging, wrinkle reduction, and extracellular matrix- boosting topical skincare are disclosed. Data and information from clinical trials that demonstrated reduced numbers of fine lines and wrinkles, r...
|
|
WO/2023/200837A1 |
Provided herein are solid dosage forms containing Prevotella bacteria useful as therapeutics, e.g., for the treatment of inflammatory disease.
|
|
WO/2023/199995A1 |
Provided is a skin external agent composition which contains taurine as crystals and has a smooth tactile feel without touching the skin. Provided are: a skin external agent composition characterized by containing fine needle-like or c...
|
|
WO/2023/197365A1 |
The present invention relates to the technical field of fusion proteins. Provided are a recombinant protein carrying a target protein and autonomously entering a eukaryotic cell, a recombinant expression vector, a recombinant bacterium, ...
|
|
WO/2023/199805A1 |
This invention contains: at least one substance from the group consisting of isoflavone, equol, glutathione, L-carnitine, bFGF, vitamin C, vitamin B1, vitamin B2, and vitamin B6; and stem cells.
|
|
WO/2023/198197A1 |
The present invention provides a free-state PLX5622 crystal form and a preparation method therefor, and in particular, provides crystal forms A, B, C, D, E and F of a compound of formula I which is a free alkali PLX5622 with the chemical...
|
|
WO/2023/194557A1 |
The present invention relates to a topical composition containing dimethylglycine and/or a salt of dimethylglycine and at least one carboxylic acid in a weight ratio of 1:0.1 to 1:10. The invention also relates to the medical and/or cosm...
|
|
WO/2023/196916A1 |
The disclosure relates to novel regimens for treating hidradenitis suppurativa by administering to a patient a pharmaceutical composition comprising a therapeutically effective amount of a peptide comprising an IL-17A binding motif and a...
|
|
WO/2023/196762A1 |
The topical cosmetic compositions and methods of the subject invention can be used to treat and/or prevent a variety of skin conditions, including, for example, age spots, acne, scars, body odor, aging-related conditions (e.g., wrinkles,...
|
|
WO/2023/193761A1 |
Disclosed are a pharmaceutical composition comprising a JAK inhibitor, a preparation method therefor and use of thereof, and particularly disclosed is a pharmaceutical composition comprising a JAK inhibitor. The pharmaceutical compositio...
|
|
WO/2023/194839A1 |
A window of opportunity skin treatment regimen and composition for preventing the onset of or treating atopic dermatitis is disclosed.
|
|
WO/2023/193956A1 |
The present invention relates to hydrogenated hyperbranched dextrins for use in preserving, protecting or restoring the eubiosis of skin microbiota and/or microbiota of mucous membranes.
|
